BioCentury
ARTICLE | Company News

NuSirt Biopharma, OWL deal

September 26, 2016 7:00 AM UTC

The companies partnered to develop diagnostic tools for trials of NuSirt’s Phase II candidate NS-0200 in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The produc...